Could you tell us what led to you forming Catalyst Clinical Research five years ago?
Yes, my journey to Catalyst Clinical Research began after my tenure as the president of Novella Clinical, a company specializing in electronic data capture (EDC) and electronic tools in clinical research, primarily focused on oncology. Novella grew significantly, benefiting from the industry's shift towards smaller and mid-sized biotech companies driving therapeutic innovation. After its acquisition by Quintiles and the subsequent integration into IQVIA, I observed a shift in the company's strategic focus.
I believed there was a persistent need for a biotech-focused, culturally aligned clinical research organization (CRO) that was nimble in decision-making. Resigning from Novella, I aimed to establish a specialty CRO dedicated to small biotechnology companies, especially focused on oncology. This led to the acquisition of Catalyst Clinical Research and Triangle Biostatistics, forming a new oncology-focused CRO with a strong emphasis on flexibility and targeted expertise.
What makes a CRO focused on biotech specific and unique?
A biotech-focused oncology CRO is distinct due to its emphasis on a professional services model that prioritizes team quality and capability support. Larger CROs often face high staff turnover, which can impact trial delivery. In contrast, our focus at Catalyst is on building a strong culture and retaining talent, resulting in lower turnover and consistent team continuity. This approach, coupled with our absence of large pharma relationships, allows us to avoid trade-offs in priority and attention, thus ensuring dedicated support for our biotech clients. We invest heavily in our culture and organizational development, making it a key differentiator in our service model.
Could you tell us more about what Catalyst currently offers?
Catalyst offers two primary solutions: Catalyst Flex and Catalyst Oncology. Catalyst Flex, built upon the foundations of Triangle Biostatistics and Catalyst Clinical Research, provides standalone services in data sciences and clinical operations across multiple therapeutic areas.
This model is highly customizable, catering to both small biotech and large pharma needs. It allows clients to manage team members efficiently, either directly or through our management.
Catalyst Oncology, on the other hand, offers an integrated approach to study delivery with strategic input in protocol design, site partnership, and comprehensive project management. This solution focuses on oncology, allowing us to provide specialized, strategic advice, such as FDA compliance and study implementation. We have established strong relationships with sites globally, enabling us to offer focused and effective solutions across oncology indications.
Aren't biotechs that entrust much of their operations to companies like Catalyst taking a significant risk? How does the industry navigate that?
Indeed, entrusting a single CRO with multiple studies does carry inherent risks, such as potential quality issues or financial instability. However, there are considerable benefits to this approach. Utilizing a single CRO allows for economies of scale and continuity of knowledge about the biotech's operations, essentially integrating the CRO as an extension of the biotech company. This model offers flexibility in team scaling as per capacity needs and efficiency in the design of clinical report forms and data analysis. While there are risks, our clients often find the benefits of scale and efficiency, coupled with close communication and updates from our leadership, mitigate these risks effectively.
Catalyst has been named one of the top ten fastest-growing companies for the fourth consecutive year. What underpins this success?
Our growth can be attributed to the clear demand for our services from smaller biotech companies, who find value in our offerings compared to larger firms. We have expanded our geographical footprint, enabling support for studies across regions like North America, Europe, Korea, and Australia.
Equally important is our company culture. We have invested in creating an engaging and stable work environment, which has led to high retention and engagement amongst our global team. This focus on culture and deliberate investment in our people has not only driven our growth but also earned us recognition as a great place to work, a testament to our balanced approach to growth and employee satisfaction.
Given the current depressed investment climate, what is your outlook for the future of CROs?
The clinical trial activity and biotech funding, while lower in 2023 compared to 2021, still align with the longer-term positive trend, particularly in oncology. Despite the current economic challenges, we see a healthy amount of investment flowing into this sector. The pace of scientific innovation, especially in immuno-oncology and targeted therapies, continues to be strong. Successful ventures and acquisitions in the biotech industry also inspire confidence in continued investment. Looking ahead, I am optimistic about the future, expecting the trend to stabilize in 2024 and potentially grow post-2025.
Can you detail Catalyst's geographical footprint and any expansion plans?
Catalyst's geographic presence spans three key regions: the US, Europe, and Asia. In the US, we typically start working with biotechs launching their initial studies. In Europe, we focus on the big five countries (UK, Spain, Germany, France, Italy), along with Switzerland, the Netherlands, Belgium, and Eastern European states. In Asia, our attention is on oncology research, with a presence in Korea, Taiwan, Japan, and China, as well as Australia. This extensive footprint caters to the varying needs of our clients and reflects our commitment to being a globally integrated CRO.
What are the main obstacles accompanying Catalyst's rapid growth?
One of the biggest challenges in our rapid growth is attracting and retaining highly qualified employees. The quality of our team is crucial, and finding skilled staff, especially in the wake of the pandemic, has been a challenge. Additionally, we are facing constraints with partner sites being fully staffed. Our response includes advocating for industry-wide adoption of technology-enabled processes, such as connecting electronic health records with EDC systems to streamline data entry. We aim to be at the forefront of process and technology innovation, collaborating with sites eager to adopt such technologies and remove redundancies.
In your opinion, where do you see the near-term possibilities in the fight against cancer, given your focus on oncology in biotech?
The near-term potential in cancer treatment lies in targeted therapies and precision medicine. The development of biomarker-driven therapies significantly increases the likelihood of FDA approval. This approach involves understanding the target patient population and their predisposition to respond to certain therapies. Advances in next-generation sequencing and high-throughput mass spectrometry are key in understanding the genetic and molecular responses expected in patients. Additionally, the integration of artificial intelligence to sift through vast amounts of data and build predictive models enhances our ability to deliver targeted medicine. As a CRO, our challenge is to translate these insights into actionable strategies for identifying and recruiting the right patient populations for clinical trials. This convergence of scientific innovation, computing power, and targeted clinical trial activity presents a significant opportunity to realize the promise of precision medicine and deliver tangible benefits to patients.
